KalVista Pharmaceuticals/KALV

$11.74

-1.26%
-
1D1W1MYTD1YMAX

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting the disease hereditary angioedema (HAE). The Company is developing sebetralstat as an oral on-demand therapy for HAE attacks and has achieved target enrollment for the phase 3 KONFIDENT clinical trial. The Company is also conducting preclinical development on oral Factor XIIa (Factor XIIa) inhibitor program, which is advancing to provide the next generation of HAE therapeutics. It is also focused on development of oral plasma kallikrein inhibitors for HAE and Factor XIIa inhibitors for HAE and other indications. Plasma kallikrein is a serine protease enzyme that is a key mediator of inflammation and edema.

Ticker

KALV

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Benjamin Palleiko

Employees

118

Headquarters

Cambridge, United States

KALV Metrics

BasicAdvanced
$501.62M
Market cap
-
P/E ratio
-$3.14
EPS
0.91
Beta
-
Dividend rate
$501.62M
0.9101
$16.88
$7.21
808.87K
5.442
-68.23%
-79.33%
-75.55%
4.644
5.663
12.2%

What the Analysts think about KALV

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 5 analysts.
169.17% upside
High $39.00
Low $24.00
$11.74
Current price
$31.60
Average price target

KALV Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$0
-
Net income
$-29M
5.07%
Profit margin
0%
-

KALV Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 9.49%
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
-$0.77
-$0.74
-$0.80
-$0.84
-
Expected
-$0.94
-$0.86
-$0.79
-$0.77
-$0.71
Surprise
-17.94%
-13.79%
1.73%
9.49%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for KalVista Pharmaceuticals stock?

KalVista Pharmaceuticals (KALV) has a market cap of $501.62M as of April 16, 2024.

What is the P/E ratio for KalVista Pharmaceuticals stock?

The price to earnings (P/E) ratio for KalVista Pharmaceuticals (KALV) stock is 0 as of April 16, 2024.

Does KalVista Pharmaceuticals stock pay dividends?

No, KalVista Pharmaceuticals (KALV) stock does not pay dividends to its shareholders as of April 16, 2024.

When is the next KalVista Pharmaceuticals dividend payment date?

KalVista Pharmaceuticals (KALV) stock does not pay dividends to its shareholders.

What is the beta indicator for KalVista Pharmaceuticals?

KalVista Pharmaceuticals (KALV) has a beta rating of 0.91. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the KalVista Pharmaceuticals stock price target?

The target price for KalVista Pharmaceuticals (KALV) stock is $31.6, which is 169.17% above the current price of $11.74. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell KalVista Pharmaceuticals stock

Buy or sell KalVista Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing